Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GLB1 | P16278 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556878 | 1.00 | LTA4H (0.54) | LTA4HPLGPOLBGLB1GBA2 | |
| Hydrochloric Acid SCHEMBL8500120 | 0.98 | LTA4H (0.52) | LTA4HPLGPOLBGLB1GBA2 | |
| SCHEMBL30751260 | 0.98 | LTA4H (0.52) | LTA4HPLGPOLBGLB1GBA2 | |
| SCHEMBL31714236 | 0.94 | LTA4H (0.49) | LTA4HPLGPOLBGLB1GBA2 | |
| SCHEMBL31714118 | 0.92 | LTA4H (0.48) | LTA4HPLGPOLBGLB1GBA2 | |
| SCHEMBL31714157 | 0.92 | LTA4H (0.48) | LTA4HPLGPOLBGLB1GBA2 | |
| SCHEMBL5562730 | 0.90 | LTA4H (0.51) | LTA4HPOLB | |
| SCHEMBL5562739 | 0.90 | LTA4H (0.51) | LTA4HPOLB | |
| SCHEMBL5563809 | 0.88 | LTA4H (0.50) | LTA4H | |
| Hydrochloric Acid SCHEMBL8501825 | 0.88 | POLB (0.46) | LTA4HPLGPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156084-A1 | Use of N-benzyl piperazine and analogues as quality of life enhancers | VALENT BRYANT G (US) | 2002-10-24 | — | — | US | claimed |
| CN-106458987-B | For treating the pyrrolidines GPR40 regulator of disease such as diabetes | 百时美施贵宝公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-108929329-A | 2- azacyclo- -5- trifluoromethyl -8- nitro benzo (thio) pyrans -4- ketone compounds | 中国医学科学院药物研究所 | 2018-12-04 | — | — | CN | disclosed |
| CN-104968654-B | Substituted 2-aminopyridine albuminoid kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. (CN) | 2018-06-01 | — | — | CN | disclosed |
| CN-107207521-A | Substituted bridged urea analogs as sirtuin modulators | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-107207496-A | Substituted bridged ring urea analogs as sirtuin modulators | 葛兰素史密斯克莱有限责任公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-104918935-B | dihydropyrazole GPR40 modulators | 百时美施贵宝公司 | 2017-07-28 | — | — | CN | disclosed |
| CN-105121426-B | Pyrrolidine GPR40 regulators | 百时美施贵宝公司 | 2017-03-29 | — | — | CN | disclosed |
| CN-106458987-A | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes | 百时美施贵宝公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106458976-A | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | 百时美施贵宝公司 | 2017-02-22 | — | — | CN | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1664063-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
| WO-2005026177-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1492794-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082877-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156084-A1 | Use of N-benzyl piperazine and analogues as quality of life enhancers | HTR2A, TPH2, TPH1 | LTA4H 2467/4885PLG 3167/4885POLB 1260/4885 |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | HRH4, HRH2, HRH3 | LTA4H 1527/4885PLG 4737/4885POLB 4011/4885 |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | LTA4H 3505/4885PLG 4730/4885POLB 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.